A clinical trial of pegylated interferon alfa-2a add-on therapy in nucleoside analogue treated Chronic hepatitis B patients to reduce recurrence after withdrawal

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012242

Enrollment

Unknown

Registered

2017-08-04

Start date

2017-09-01

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

control group :NAs

intervention group:NAs+peg-IFNa-2a(48 weeks)

control group:NAs+peg-IFNa-2a(72 weeks)

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. received nucleoside analogue therapy for more than 3 years; 2. aged at least 16 years; 3. HBV-DNA<100IU/ml; 4.HBeAg<1.00S/CO.

Exclusion criteria

Exclusion criteria: 1. drug allergy history; 2. cirrhosis or other chronic liver diseases, other serious diseases; 3. pregnancy and breastfeeding; 4. long history of drinking; 5. previous immunological therapy; 6. contraindications for peg-IFNa-2a therapy.

Design outcomes

Primary

Measure	Time frame
the level of HbsAg;the level of HbsAb;	—

Countries

China

Contacts

Public ContactBIHUI ZHONG

Division of Gastroenterology and Infectious diseases, The First Affiliated Hospital of Sun Yat-sen University

sophiazhong@hotmail.com+86 020-87755766-8172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026